Oncology
CRC: Risk Factors, Newly Approved Therapies and the Role of the Pharmacist in CRC Therapy
The objective of this online program is to help educate and support pharmacists in the KSA in understanding the current landscape of CRC - genetic aberrations, risk factors, incidence, and selected newly approved therapies. There is also discussion about common adverse events associated with guideline-recommended treatment of CRC, and the role of pharmacists to help mitigate these adverse events in their patients.
This program is approved for the following professions: Medical Oncology, Pharmaceutical Sciences, Clinical Pharmacy, Pharmaceutical administration and outcomes, Pharmacy.
DURATION
2 hrs
PROFESSION
Pharmacy, Specialist
# OF CREDITS
2.0
ACCREDITATION
SCFHS
EXPIRY DATE
2024-07-26
Recent literature demonstrates that colorectal cancer (CRC) is now the most common type of cancer in the Kingdom of Saudi Arabia (KSA). For people undergoing treatment for CRC, pharmacists will play a pivotal role in their health care team.
The objective of this online program is to help educate and support pharmacists in the KSA in understanding the current landscape of CRC – genetic aberrations, risk factors, incidence, and selected newly approved therapies. There is also discussion about common adverse events associated with guideline-recommended treatment of CRC, and the role of pharmacists to help mitigate these adverse events in their patients.
This program is supported by Novartis.
Faculty
Mohammad Shouki Bazarbashi, MD, MPH
Nora Alkhudair, reviewer
Learning objectives
Upon completion of this continuing education program, participants will be better able to:
- Describe relevant genetic aberrations seen in CRC.
- Outline risk factors and preventive strategies for CRC.
- Integrate information about newly approved therapies into the treatment of CRC.
- Recognize common adverse events associated with the treatment of CRC and implement strategies to mitigate them.
Accreditation
This program is accredited by the Saudi Commission for Health Specialties for 2.0 CPD Hour(s).
Activity Accreditation Number: ACA-20230002488.
Credits are reported to the Saudi Commission for Health Specialties on a monthly basis. Please ensure that your Saudi Commission ID is accurate in your profile and allow sufficient time for credits to appear in your Mustamir account.
This program is approved for the following professions: Medical Oncology, Pharmaceutical Sciences, Clinical Pharmacy, Pharmaceutical administration and outcomes, Pharmacy.